We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: January 31, 2006
Last Update Posted: July 28, 2015
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Helse Stavanger HF
A randomized controlled trial in patients with type 1 diabetes, assessing the metabolic effects of accurate blood sugar results and education. A systematic approach in self-monitoring blood glucose will improve metabolic control in type 1 diabetes patients. Education in SMBG combined with a high analytical quality instrument for SMBG, introduced in a systematic and thorough way will improve HbA1c by 0,5% and keep it over a period of 9 months.

Condition Intervention Phase
Diabetes Mellitus, Type 1 Behavioral: Use and interpretation of blood glucose results Drug: Insulin dosing based on SMBG chart and education Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Official Title: Randomized Controlled Trial Studying the Metabolic Effects of Accurate Blood Sugar Results and Education in Type 1 Diabetes

Resource links provided by NLM:

Further study details as provided by Helse Stavanger HF:

Primary Outcome Measures:
  • HbA1c % [ Time Frame: 9 months ]

Secondary Outcome Measures:
  • Hypoclycemic events [ Time Frame: 9 months ]
  • Measurement quality of blood glucose instrument [ Time Frame: 9 months ]
  • Frequency of SMBG [ Time Frame: 9 months ]
  • Satisfaction [ Time Frame: 9 months ]
  • New learning points for patients [ Time Frame: 9 months ]
  • Confidence in new instrument quality [ Time Frame: 9 months ]

Estimated Enrollment: 140
Study Start Date: October 2004
Study Completion Date: December 2006
Primary Completion Date: August 2006 (Final data collection date for primary outcome measure)
Detailed Description:
  • Written informed consent 130 patients with type 1 diabetes to be included
  • age 18-70
  • HbA1c of 8% or higher, variation in HbA1c over the last 18 months sholuld be <1,5%
  • Treated with multiple insulin injections or insulin pumps
  • Variation in weight less than 5kg within last year
  • Using SMBG on a daily basis
  • Mental capacity and stability to participate
  • No hypoglycemia unawareness
  • No likelihood that patient will drop out or not perform according to protocol
  • Continious recruitment from the outpatient clinic at Stavanger University Hospital from October 2004-October 2005
  • 9 months follow-up
  • Possible 12 month extension after initial
  • Intervention group receives new SMBG instrument, education and advice on treatment changes at baseline, 1,2,3,6 and 9 months. Control group continues regular care following national guidelines of Norway. This includes visits usually every 3-6 months at the outpatient clinic and possibly with their GP in addition.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 70 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Hba1c 8% or higher, less than 1,5% variation within last year
  • Age 18-70
  • Multiinjections or insulin pumps
  • Stable weight (<5kg variation last year)
  • Mentally stable

Exclusion Criteria:

  • Hypoglycemia unawareness
  • Mental incapacity
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00284232

Stavanger University Hospital
Stavanger, Norway
Sponsors and Collaborators
Helse Stavanger HF
Principal Investigator: Svein Skeie, MD PhD Stavanger Health Research
  More Information

Responsible Party: Helse Stavanger HF
ClinicalTrials.gov Identifier: NCT00284232     History of Changes
Other Study ID Numbers: Measure 2004
First Submitted: January 27, 2006
First Posted: January 31, 2006
Last Update Posted: July 28, 2015
Last Verified: July 2015

Keywords provided by Helse Stavanger HF:
Self-monitoring blood glucose (SMBG)
Diabetes treatment
quality of care

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 1
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases